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Abstract
Fabry disease is an X-linked disorder of glycosphingolipid metabolism that results in progressive accumulation of neutral
glycosphingolipids, (predominately globotriaosylceramide; GL-3) in lysosomes, as well as other cellular compartments and
the extracellular space. Our aim was to characterize the cardiac phenotype of male knock-out mice that are deficient in
alpha-galactosidase A activity, as a model for Fabry disease and test the efficacy of Enzyme Replacement Therapy with
agalsidase-beta. Male mice (3–4 months of age) were characterized with awake blood pressure and heart rate
measurements, cardiac echocardiography and electrocardiography measurements under light anesthesia, histological
studies and molecular studies with real-time polymerase chain reaction. The Fabry knock-out mouse has bradycardia and
lower blood pressure than control wild type (CB7BL/6J) mice. In Fabry knock-out mice, the cardiomyopathy associated mild
hypertrophy at echography with normal systolic LV function and mild diastolic dysfunction. Premature atrial contractions
were more frequent in without conduction defect. Heart weight normalized to tibial length was increased in Fabry knock-
out mice. Ascending aorta dilatation was observed. Molecular studies were consistent with early stages of cardiac
remodeling. A single dose of agalsidase-beta (3 mg/kg) did not affect the LV hypertrophy, function or heart rate, but did
improve the mRNA signals of early cardiac remodeling. In conclusion, the alpha-galactosidase A deficient mice at 3 to 4
months of age have cardiac and vascular alterations similar to that described in early clinical stage of Fabry disease in
children and adolescents. Enzyme replacement therapy affects cardiac molecular remodeling after a single dose.
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Introduction
After initial clinical descriptions, mutations in the alpha-
galactosidase A (AGAL) gene were found to be responsible for
Fabry disease, which is an X-linked disorder of glycosphingolipid
metabolism that results in progressive accumulation of neutral
glycosphingolipids, (predominately globotriaosylceramide; GL-3)
in lysosomes, as well as other cellular compartments and the
extracellular space [1]. The prevalence of Fabry mutation ranges
from 1 in 40,000 to 1:117,000 in United States and Australia to
1:833,000 in Northern Portugal, the majority of them Caucasians
[2]. These figures may underestimate the real prevalence of the
disease as many patients go undiagnosed due to rarity of this
disorder and phenotypic variation of the clinical features,
especially in females. Much higher estimates of prevalence (e.g.,
1 in 4,000) have been obtained from a newborn screening project,
most of which were so-called ‘‘late-onset’’ variants with some
residual enzyme activity [3]. Most affected males have little, if any,
alpha-galactosidase A activity, and the deposition of GL-3 occurs
primarily in vascular endothelial cells as well as epithelial and
smooth muscle cells throughout the body. Early clinical manifes-
tations of the disease include angiokeratoma, acroparesthesias,
episodic pain ‘‘crises’’, hypohydrosis, and gastrointestinal com-
plaints [1].
Progressive GL-3 accumulation in the microvasculature and
parenchyma leads to microvascular dysfunction, occlusion, and
ischemia. Recent reports have described increased inflammation,
oxidative stress, and circulating myeloperoxidase [4] which
appears to be associated with vasculopathic events [5]. In adult
males with Fabry disease, the renal, cardiovascular and cerebro-
vascular manifestations such as proteinuria, chronic kidney disease
and kidney failure, cardiac arrhythmias, hypertrophic cardiomy-
opathy and strokes lead to early death during the fourth and fifth
decade of life [1,6,7]. A late onset cardiac variant has been
described in male patients which is associated with progressive
cardiac fibrosis and ultimate death in the 6
th decade of life from
the cardiac disease with preserved renal function [8,9].
Recent studies have emphasized the importance of controlling
proteinuria with inhibitors of the renin-angiotensin-aldosterone
system in patients receiving enzyme replacement therapy (ERT)
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e33743[10] but even with stabilization of kidney function, some of these
patients still experience cardiac events, including bradyarrhyth-
mias, ventricular premature contractions and sustained ventricular
arrhythmias and conduction delays [11,12] as have been described
in untreated patients [8,13]. The cardiac manifestations in adults
with Fabry disease, with emphasis on the non-obstructive,
concentric hypertrophic cardiomyopathy are well described
[8,14,15,16]. Kampmann et al. have studied a large number of
adolescents with Fabry disease; some present with early symptoms
and signs of cardiac involvement [17], findings that have been
confirmed by reports from Fabry registries [18,19].
Mouse knock-out (KO) models for Fabry disease have been
described [20,21]. Shayman et al. have studied large vessel
reactivity and pathology in this model [4,22,23,24,25]. Recent
work by Rozenfeld et al has described myocardial alterations in
this model, and the response to ERT given at biweekly intervals
for 2 months [26]. In the present study, we found that Fabry KO
male mice have bradycardia, low systemic blood pressure and mild
hypertrophic cardiomyopathy when compared to the control wild-
type (WT) C57BL/6J mice. Molecular studies are consistent with
early cardiac remodelling, and these changes were reversed rapidly
in response to a single dose of ERT.
Methods
Ethics Statement
This study conforms to European Union Council Directives
(86/609/EEC) regarding the care and use of laboratory animals,
and the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication No. 85–23, revised 1996. The Institutional Animal
Care and Use Committee approved live animal procedures
conducted at the University of Alabama at Birmingham (Animal
Project Number 10XX08339).
Animal Model
Breeding pairs of the Fabry KO mouse were obtained from the
National Institutes of Health (Bethesda, MD). This model as been
previously used by Eitzman et al. to analyze vascular function [22].
Control WT animals were gender- and age-matched C57BL/6J
mice obtained from the Charles River Laboratories. Male animals
were used, and mice were provided standard chow (A04, Scientific
Animal Food Engineering, Epinay sur Orge, France) and drank
tap water ad libitum.
Blood Pressure, Electrocardiography and
Echocardiography Measurements
Systolic blood pressure (SBP) on trained conscious mice was
measured by tail cuff plethysmography using a BP2000 Visitech
model as published previously [27]. Conscious heart rate (HR) was
extracted from the pulse signal. Electrocardiograms (ECGs) were
recorded over a 10 min period in 3–4-month-old mice under light
anesthesia with isoflurane. Arrhythmia was detected by analysis of
the tachogram of the recording (10 min tracings). Tachograms
were constructed from automatic R wave detection (ECG-Auto
EMKA, France) and RR plotted against time. All abnormal RR
intervals were checked for validation and labeling. ECG intervals
were measured from short recordings on average beats, construct-
ed from 200 consecutive QRST complexes. Intervals were
determined semi-automatically from a library of QRST wave-
forms sampled from the tracing. Average beats were checked and
intervals set using the first derivative of the tracing. PQ was
measured from the onset of P wave to the onset of the QRS wave.
QRS duration was measured from the onset of the Q wave to the
end of high-amplitude electrical events, as detected on the first
derivative. The QT interval was measured from the onset of the Q
wave to the last detectable electrical event on the first derivative.
QT interval was corrected for heart rate by drawing the linear
regression line from individual beats for each mouse, and was
expressed as the value at a RR of 150 msec [28].
Echocardiography was performed on lightly anesthetized mice
(isoflurane, Abbott, in oxygen), as described previously [29]. A
small number of animals appeared to have more severe
bradycardia in response anesthesia, and these animals were not
included in the analysis of the echocardiograhy results to avoid
non-specific rate-related changes. Briefly, the heart was visualized
in the long axis parasternal view for M-mode left ventricle (LV)
dimension measurement and posterior wall pulse wave tissue
Doppler measurement. An apical 4- to 5-chamber view was
obtained from the subcostal view for diastolic function assessment
with pulse wave spectral LV inflow and outflow and for pulse wave
tissue Doppler measurement of the mitral annulus velocities [29].
Relative wall thickness was calculated as (IVST+LVPWT)/LV
EDD (IVST, interventricular wall thickness; LVPWT, LV
posterior wall thickness).
Histochemistry and Quantification of Non-Vascular
Collagen
Following intra-aortic perfusion with phosphate-buffered saline,
hearts were excised from mice anesthetized with pentobarbital
(50 mg/kg, i.p.) and fixed in 10% neutral buffered formalin. Fixed
hearts were transected perpendicular to the long axis through the
ventricles at their widest point and processed routinely for paraffin
sectioning. Both portions were embedded so that sections
contained 2 cross sections. Sections were cut 5 mm thick and
stained with hematoxylin and eosin or Pirosirius Red [30]. Fields
of the anterior, posterior and lateral left ventricle and the
intraventricular septum were digitally photographed at 10x
objective magnification with routine transmitted light and with
polarization. For each field, myocardial area was determined by
extraction of the green color channel, thresholding, and measure-
ment with Image Pro Plus 6.2 software (MediaCybernetics, Inc.
Bethesda MD). Myocardial collagen was determined by inverting
polarized images, thresholding, deleting normal perivascular
collagenous tissue and measurement of remaining areas. Collagen
area was expressed as a percentage of the total myocardial area for
each field. Myocyte diameters were measured perpendicular to the
long axis of the sarcomeres from unbranched areas of the
myocytes near an intercalated disk.
RNA Purification, cDNA Synthesis and Reverse
Transcriptase-Polymerase Chain Reaction (RT-PCR)
Total RNA was extracted from the hearts of control and Fabry
KO mice after being homogenized in Trizol (Trisol Reagent,
Invitrogen), following the instructions of the manufacturer. Total
RNA samples were treated with DNase I (AmbionH, Applied
Biosystems, Courtaboeuf, France) and reverse-transcribed using
random hexamers (Invitrogen, Cergy Pontoise, France) and the
DNA polymerase SuperScriptII (Invitrogen). Real-time PCR was
carried out on the iCycler (Biorad) using gene-specific primers to
quantify the relative abundance of each gene with SYBR Green I
as the fluorescent molecule as described [31]. The primers used
are listed in Table S1. The GAPDH gene was used as reference
gene for normalization. Relative copy number of the target genes
was calculated with the 2
(–DDCt) method, as described [31].
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Mice were inject via tail vein with a single injection of
agalsidase-beta (FabrazymeH, Genzyme Corporation, Cambridge
MA, USA) at a dose of 3 mg/kg, as previously described [20]; GL-
3 levels in the heart reached a nadir at 3 weeks following a single
intravenous injection of agalsidase-beta at 3 mg/kg, which is the
timing and dose of agalsidase-beta used in the present study.
Control animals received similar volumes of normal saline. Mice
underwent physiologic and echocardiographic assessment prior to
injection, and then at 3 weeks following injection, at which point
the cardiac GL-3 content was stably reduced by 80% [20].
Statistics
Data are expressed as mean 6 SE. Student’s two-tailed t tests
were used to compare unpaired data between two groups. If the
global test was significant, pair-wise comparisons were performed
with a Tuckey-Kramer test. P * 0.05 was considered significant.
Results
Systolic Blood Pressure, Heart Rate, ECG and Cardiac
Weight Measurements
Systolic blood pressure was lower for male Fabry KO mice than
for male wild-type mice (WT) (Figure 1A). In addition, heart rate
was significantly slower in the Fabry KO mice than the WT
controls (Figure 1B).
The measurements of RR intervals with surface ECG record-
ings showed prolonged RR intervals for Fabry KO mice compared
to WT controls (Table 1). and the standard deviations of the RR
intervals (SDNN) were significantly increased in the Fabry KO
mice compared to the WT controls after normalization for heart
rate (Fabry KO: 12% vs WT: 5%). There were no differences in
PQ, QRS, or corrected QT intervals (Table 1). Premature atrial
contractions were more frequently observed in Fabry KO mice
than WT mice (Table 1).
Heart weight was increased for Fabry KO mice, compared to
WT mice when normalized to body weight (Figure 2A) or tibial
length (Figure 2B).
Left Ventricle and Aortic Structural Alterations
The echocardiography results for 4 month-old mice are
summarized in Table 2. There were significant increases in LV
mass normalized to body weight (LV mass/BW) for Fabry KO
mice compared to the WT age-matched controls (4.860.32 versus
4.260.14 mg/g; p,0.05). Despite the lower systolic blood
pressure measurements, there was also a significant increase in
the aortic diameter during diastole for Fabry KO mice compared
to the WT controls (1.660.07 versus 1.460.03 mm; p,0.01).
Aortic dilation was not associated with aortic valvular regurgita-
tion (data not shown).
Left Ventricular Functional Alteration
Global LV systolic function was similar in Fabry KO mice as
compared to age-matched WT mice, as assessed with echographic
analysis of ejection fraction and systolic velocity of the mitral
annulus by tissue Doppler (Table 2). Fabry KO mice had mild
diastolic LV dysfunction as depicted with the decrease in Ea
velocity, without change in the isovolumic relaxation time.
Left Ventricular Histologic Alteration
Routine histological stains (Figure 3A) did not reveal any
structural difference between 4 month-old Fabry KO and wild
type mice. Morphometric analysis showed identical myocyte
diameters (Table 3), and electron micrographs showed occasional
electron dense lamelated inclusion bodies, similar to previous
descriptions (data not shown) [20].
Figure 1. Comparison of Fabry Knock-out (KO) mice to wild
type C57BL/6NJ mice: Tail Cuff Measurements. (A) Systolic blood
pressures (mm Hg) and (B) Heart rates (beats per minute) were
determined with tail-cuff measurements in awake animals. Data
represent the means 6 SE for 9 Fabry KO and 8 wild type male mice.
Statistical significance was determined by unpaired, two-tailed t-test:
*P,0.05.
doi:10.1371/journal.pone.0033743.g001
Table 1. ECG results in 3–4 month old WT and Fabry KO mice.
WT Controls Fabry KO
Number 12 16
RR interval (msec) 11764.5 13565.6*
SDNN (msec) 6.460.7 16.261.4*
PR interval (msec) 3660.4 3760.8
QRS interval (msec) 1660.5 1660. 6
QTc150 interval (msec) 4961.2 4762.0
APC (%) 33 93**
Surface ECGs were obtained in lightly anesthesized mice. Data represent the
means 6 SE. Statistical significance was determined by pair-wise comparisons
with a Tuckey-Kramer test, or x
2 analysis.
WT, wild-type; KO, knockout; SDNN, standard deviation of normal RR intervals;
APC, %of animals with atrial premature contractions during 10 min recording.
*P,0.05,
**P,0.05 by for x
2 analysis.
doi:10.1371/journal.pone.0033743.t001
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in non-vascular collagen staining in the myocardium of male
Fabry KO mice compared to WT mice (Figure 3C–B) and no
predominant area of fibrosis in Fabry KO mice.
LV Molecular Alterations in Fabry KO Mice
We examined myocardial alterations that could be associated
with cardiac remodeling and dysfunction by analyzing mRNA
expression for atrial natriuretic factor (ANF) brain natriuretic
peptide (BNP), plasminogen activator inhibitor-1 (PAI-1); connec-
tive tissue growth factor (CTGF), thrombospondin 1 (TSP1), and
thrombospondin 2 (TSP2). As shown in Figure 4A, ANF and BNP
mRNA levels normalized to GAPDH levels were significantly
increased in male Fabry KO mice compared to wild type controls.
PAI-1 and CTGF mRNA levels were increased in male Fabry KO
mice, as compared to wild type. Also shown in Figure 4 are the
normalized values for TSP1 and TSP2, members of the
matricellular protein family, which are up-regulated during
cardiac stress, injury and remodeling [32]. TSP2 but not TSP1
mRNA levels were increased in male Fabry KO mice compared to
wild type controls. The mRNA levels for collagen 1a and collagen
3a, the matrix metallo-proteinases 2 and 9 were not altered in
Fabry KO mice (data not shown).
Systolic Blood Pressure, Heart Rate, ECG and Cardiac
Weight Measurements: Effects of ERT
The measurements of RR intervals with surface ECG record-
ings showed identical RR intervals and the standard deviation of
the RR intervals, and the frequency of premature atrial
contractions for Fabry KO mice compared to Fabry KO mice
treated with 3 mg/kg intravenous ERT 3 weeks before (Table 4).
There were no significant differences in PQ, QRS, or corrected
QT intervals (data not shown).
ERT had no effect 3 weeks after injection on heart weight for
Fabry KO mice, when normalized to body weight (Figure 5A)o r
tibial length (Figure 5C). There was no effect 3 weeks after injection
on heart weight for WT mice, when normalized to body weight
(Figure 5B) or tibial length (Figure 5D).
Left Ventricle and Aortic Structural Alterations with ERT
The echocardiography results for 6–7 month-old Fabry KO
mice are summarized in Table 5 for untreated mice and those who
received a single injection of ERT 3 weeks before evaluation.
While there was no significant effect on the LV mass estimates,
there was a significant increase in relative wall thickness for
Fabry KO mice treated with ERT compared to the untreated KO
Figure 2. Comparison of Fabry Knock-out (KO) mice to wild
type C57BL/6NJ mice: Heart Weights. Body weights (g), heart
weights (mg) and tibial lengths (mm) were measured at sacrifice. Data
represent the means 6 SE for 9 Fabry KO and 11 wild type male mice.
Statistical significance was determined by unpaired, two-tailed t-test:
*P,0.05.
doi:10.1371/journal.pone.0033743.g002
Table 2. Echocardiographic evaluation of 3 to 4 month-old
Wild type and Fabry Knock Out (KO) mice.
Wild Type Fabry KO
Number 12 11
Body Weight (g) 27.660.4 31.160.5
Age (weeks) 18.860.1 18.260.3
Heart Rate (beats per min) 51867 52169.4
Cardiac and vascular remodeling
LA Diameter (mm) 2.260.08 2.760.10
LA Diameter/BW (mm/g) 0.160.01 0.160.03
LV EDD/BW (mm/g) 0.1560.01 0.1560.01
LV mass/BW (mg/g) 4.260.14 4.860.32*
Relative Wall Thickness 0.460.02 0.460.02
Diastolic Ao (mm) 1.460.03 1.660.07**
Left Ventricular Systolic Function
LV Ejection Fraction (%) 82627 9 63
Vcfc, circumference/sec 3.2560.12 3.1560.31
Sa (cm/s) 2.760.20 2.960.12
Spw (cm/s) 3.160.20 3.260.16
Left Ventricular Diastolic Function
IVRT (ms) 17.060.60 17.061.1
Ea (cm/s) 5.560.24 4.560.40**
Epw (cm/s) 4.460.19 4.060.40
E/Ea 19.160.8 21.761.7
Data represent the means 6 SE. Statistical significance was determined by
unpaired, two-tailed t-test: *P,0.05: **P,0.01.
Abbreviations: LA, left atrium; LV, left ventricle; LV EDD, left ventricular end
diastolic diameter; Vcfc, velocity of shortening of circumferential fibers; Sa, Spw:
maximal systolic velocity of the mitral annulus and posterior wall; IVRT:
isovolumic relaxation time; Ea and Epw: maximal diastolic velocity of the mitral
annulus and posterior wall; E, maximal velocity of LV inflow.
doi:10.1371/journal.pone.0033743.t002
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diameter after treatment (3.960.6 vs 4.260.15, ns) without change
in wall thickness (septum: Fabry mice ERT 1.060.03, Fabry mice:
0.960.02; posterior wall Fabry mice ERT 0.860.04, Fabry mice:
0.760.03). There was a significant decrease in the aortic diameter
during diastole for Fabry KO mice treated with ERT compared to
the age-matched KO controls (1.760.05 versus 1.660.04 mm;
p,0.01).
Left Ventricular Functional Alterations in Fabry KO Mice
with ERT
The heart rates obtained in 6–7 week old mice undergoing
echocardiography with isoflurane anesthesia were the same for
untreated Fabry KO mice compared to age-matched Fabry KO
mice that had received ERT (3 mg/kg) as a single IV injection 3
weeks before evaluation (Table 5).
LV systolic function, as assessed by echocardiography was
similar in ERT-treated Fabry KO mice as compared to age-
matched untreated KO mice (Table 4). ERT-treated Fabry KO
Figure 3. Left Ventricular Histology of wild type C57BL/6NJ mice to Fabry Knock-out (KO) mice. (A) Wild type mouse, left panel; Fabry KO
mouse, right panel; 406magnification. Hearts were perfusion fixed and sections obtained for staining for hematoxylin and eosin. (B) Pirosirius Red
staining for non-vascular collagen (Wild type mouse, left panel; Fabry KO mouse, right panel; 206magnification). (C) Pirosirius Red staining for non-
vascular collagen, expressed as the percentage of the total myocardial area for each field.
doi:10.1371/journal.pone.0033743.g003
Table 3. Myocyte Diameter and Picrosirius Red Staining of 4-
month old Fabry KO and WT mice.
WT Controls Fabry KOs
Myocyte diameter (mm) 82.669.9 79.164.9
Collagen content (%) 0.005660.0025 0.004660.0008
doi:10.1371/journal.pone.0033743.t003
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controls.
LV Molecular Alterations in Fabry KO and WT Mice
Treated with ERT
As shown in Figure 4B, ANF and BNP mRNA levels
normalized to GAPDH levels were significantly decreased in male
Fabry KO mice 3 weeks after ERT treatment compared to
untreated KO controls. PAI-1 and CTGF mRNA levels were
decreased in ERT-treated male Fabry KO mice, as compared to
untreated KO controls. TSP2 but not TSP1 mRNA levels were
decreased in ERT-treated male Fabry KO mice compared to
untreated KO controls.
The effects of ERT were also examined in WT controls 3 weeks
after a single IV injection (3 mg/kg), compared to untreated age-
matched WT controls. There was a significant decrease in BNP
mRNA normalized to GAPDH levels in ERT-treated WT mice,
but there were not any effects of ERT on any of the mRNA levels
examined in this series compared to WT concurrent control male
mice (Figure S1).
Discussion
In the present study, we define the cardiac phenotype in male
Fabry KO mice. We found that these mice have bradycardia and
low systemic blood pressures compared to the control WT strain,
as well as mild hypertrophic cardiomyopathy on echocardiogra-
phy and gravimetry. The heart rates and systolic blood pressures
reported herein for the WT mice are very similar to previous
reports [33,34].
Thus KO Fabry mice displayed a mild hypertrophic cardio-
myopathy with structural and functional alteration similar to that
described for the early stages of human myocardiopathies. Our
results are similar to and extend the findings of Rozenfeld et al.,
who have described changes in passive pressure volume curves and
contractility measurements in the male mouse KO model of Fabry
disease, but did not document hypertrophy as assessed by cardiac
weight normalized to tibial length or echo cardiographic
assessment of left ventricular mass [26].
The initial descriptions of the KO model of Fabry disease were
used for pharmacokinetic studies of ERT, and did not evaluate the
phenotype of these animals (‘‘.no clinical disease phenotype and
survived a normal laboratory lifespan’’[20]). Shayman et al. have
studied large vessel reactivity and pathology in this model
[4,22,23,24,25,35] but did not evaluated the cardiac findings.
The most striking aspect of the cardiac phenotype in the KO
mice was hypotension and bradycardia, compared to the WT
controls. Autonomic nervous system alteration, as assessed on
heart rate variability, was described in children and adolescents
with decreased heart rate variability in boys [17] and could
Figure 4. Comparison of wild type C57BL/6NJ mice (open bars) to Fabry Knock-out (KO) mice (black bars): mRNA levels. Real-time
PCR amplification of indicated mRNA targets, normalized to GAPDH mRNA level. ANF, atrial natriuretic factor; BNP, brain natriuretic peptide; PAI-1,
plasminogen activator inhibitor -1; CTGF, connective tissue growth factor; TSP1, thrombospondin 1; TSP2, thrombospondin 2; Statistical significance
was determined by unpaired, two-tailed t-test: *P,0.05. (A). Comparison of wild type C57BL/6NJ mice (open bars) to Fabry Knock-out (KO) mice
(black bars): mRNA levels. (B). Comparison of Fabry Knock-out (KO) mice (black bars) to Fabry Knock-out (KO) mice (gray bars) 3 weeks after a single
intravenous treatment with agalsidase-beta at 3 mg/kg: mRNA levels.
doi:10.1371/journal.pone.0033743.g004
Table 4. ECG results in 6–7 month old Fabry KO mice: effects
of ERT.
KO Controls KO ± ERT
Number 11 11
RR (msec) 13565.6 14364
SDNN (ms) 16.762 19.762.2
APC (%) 45.6 54
Surface ECGs were obtained in lightly anesthesized mice. Data represent the
means 6 SE. Statistical significance was determined by pair-wise comparisons
with a Tuckey-Kramer test, or x
2 analysis.
WT, wild-type; KO, knockout; SDNN, standard deviation of normal RR
intervals;APC, % of animals with atrial premature contractions during 10 min
recording.
doi:10.1371/journal.pone.0033743.t004
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disease. Our results suggest that the mouse model have also
alteration of the autonomic nervous system, as depicted by
bradycardia and time domain parameters of heart rate variability
suggesting increase in variability. The change in time domain
parameter (SDNN) could be partly accounted for by bradycardia
itself with increasing dispersion of the RR but also by a greater
influence of parasympathetic activity which could also be
responsible for the lower blood pressure. Comparison with the
human findings would need a complete autononic nervous system
evaluation in mice.
Endothelial dysfunction was described in human Fabry disease
with inflammation and increased oxidative stress within the vessel
wall [4]. GL-3 accumulation occurs primarily in endothelial cells
with impairment of vessel reactivity [4,25]. Alteration in endo-
thelial function, with the consequent change in smooth muscle
cells, could be related to our findings of ascending aorta dilatation
in the KO model that does not appear to be explained by
hemodynamic changes. This has also been recently described in
the human disease [36].
Cardiac abnormalities in Fabry disease are characterized
mainly by LV wall thickening without significant dilatation, and
LV hypertrophy [14]. Systolic function is largely preserved in most
affected individuals, but diastolic dysfunction is a relatively
common finding even at early stage of the disease [14,17]. In
the mouse model, we found LV functional alterations with mild
alteration of diastolic function, as depicted with Tissue Doppler
interrogation, and no systolic alteration. This is very similar to the
findings in human at early stages of the cardiac disease [37,38,39].
Moreover, a good relationship was shown between tissue Doppler
echocardiographic data and mechanical properties of human
cardiac myofilaments obtained from myocardial biopsies [38]. The
findings that the mouse model has mild cardiac involvement
detectable with tissue Doppler suggest that this specific interroga-
tion in human has to be performed for early detection of cardiac
involvement, inasmuch as the efficiency of the replacement
therapy is dependent on early onset of treatment [15]. We also
found evidence of cardiac remodeling at the molecular level, with
increased mRNA levels, for atrial natriuretic factor (ANF) brain
natriuretic peptide (BNP), plasminogen activator inhibitor-1 (PAI-
1); connective tissue growth factor (CTGF), and thrombospondin 2
(TSP2).
Our results suggest that atrial arrhythmias could be associated
with early cardiac involvement in Fabry disease. Although more
than 60% of patients with Fabry disease have evidence of cardiac
involvement, the prevalence and clinical significance of arrhyth-
mia in Fabry disease are unknown. Shah and colleagues studied 78
consecutive patients (mean age 43.5615.0 years, 43 males) with
Fabry disease [40]. Three patients (3.9%) had persistent atrial
fibrillation, and 8 (13.3%) had paroxysmal atrial fibrillation. Five
males (8.3%) had nonsustained ventricular tachycardia with a
maximal left ventricular wall thickness .20 mm. Age, left atrial
diameter, maximal left ventricular wall thickness, left ventricular
mass index, and angina were univariate predictors of atrial
fibrillation. During follow-up, there was 1 sudden cardiac death, 4
patients received pacemakers for bradyarrhythmias, and 1 patient
received a biventricular pacemaker and an internal cardiac
defibrillator. The high incidence of arrhythmias and pacemaker
implantation and sudden cardiac death suggests that arrhythmia
has a significant impact on the natural history of Fabry disease.
The mouse model did not, however, displayed ventricular
arrhythmias possibly because the mice were relatively young.
Figure 5. Comparison of untreated Fabry Knock-out (KO) and WT mice to ERT-treated KO mice and ERT-treated WT mice: Heart
Weights. Body weights (g), heart weights (mg) and tibial lengths (mm) were measured at sacrifice. Data represent the means 6 SE for 11 Fabry KO
and 9 wild type male mice. Statistical significance was determined by unpaired, two-tailed t-test: *P,0.05.
doi:10.1371/journal.pone.0033743.g005
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recapitulate all cardiac feature of human Fabry disease: 1)
Ventricular arrhythmias or conduction (atrioventricular or intra-
ventricular) defect were not found; 2) LV hypertrophy and GL-3
accumulation was mild or absent; and 3) Accelerated arterioscle-
rosis and vascular thrombosis was not evident in the mouse model,
at least at the ages we examined in this series.
Over the last decade, the natural history of Fabry disease
appears to have changed. With the use of ERT and antiprotei-
nuric therapy, renal outcomes have improved and currently the
most common cause of death is cardiac involvement and sudden
cardiac death [41,42] Electrocardiographic changes that have
been described in Fabry disease include atrial fibrillation,
atrioventricular conduction abnormalities, left ventricular hyper-
trophy, and repolarization abnormalities [17,43]; [44]. Cardiac
symptoms in patients with Fabry disease include bradycardia,
shortness of breath with exertion, vasospastic and/or exertional
angina pectoris, and syncope [45,46]. Long term treatment with
ERT has been shown to reduce LV hypertrophy, and suggested
that early treatment may yield better long-term cardiac outcomes
and exercise capacity [15].
Whether or not these abnormalities in heart rhythm or rate, as
well as the cardiac remodeling will respond to ERT, and/or other
forms of adjunctive therapy [47] are questions that can be
addressed in the Fabry KO mouse despite the limitations of the
model [1]. We have found changes in the cellular phenotype in
this model, 3 weeks following a single intravenous injection of
3 mg/kg agalsidase-beta, a dose and interval chosen to maximize
the reduction in cardiac GL3 content [20]. Rozenfeld et al.
observed improvement in left ventricular contractility following
longer treatment periods (4 injections over 2 months) of a much
lower dose of ERT (0.5 mg/kg) [26]. Alternate dosing schedules as
well as consideration of alternative forms of therapy [48] for this
condition are important avenues for future research.
Supporting Information
Figure S1 Comparison of WT mice treated with ERT to WT
mice 3 weeks after a single intravenous injection with agalsidase-
beta at 3 mg/kg: mRNA levels. Wild type C57BL/6NJ mice (open
bars) compared to ERT-treated WT mice (gray bars). Real-time
PCR amplification of indicated mRNA targets, normalized to
GAPDH mRNA level. ANF, atrial natriuretic factor; BNP, brain
natriuretic peptide; PAI-1, plasminogen activator inhibitor -1;
CTGF, connective tissue growth factor; TSP1, thrombospondin 1;
TSP2, thrombospondin 2; Statistical significance was determined
by unpaired, two-tailed t-test: *P,0.05.
(TIF)
Table S1 Primers sequences.
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